Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor The study by Dr Mismetti and colleagues1 for the Prévention du Risque d’Embolie Pulmonaire par Interruption Cave 2 (PREPIC2) Study Group reinforced some of the findings of the original PREPIC trial2 and discounted others.
As in the PREPIC study, at the 3-month end point, there was no advantage to filter placement in patients with venous thromboembolism receiving anticoagulation.3 This result validates the current recommendations of numerous societies as to the lack of added benefit of an inferior vena cava filter in the treatment of a patient with venous thromboembolism who receives adequate anticoagulation.4
Hoffer EK. Inferior Vena Cava Filter and Recurrent Pulmonary Embolism. JAMA. 2015;314(7):728-729. doi:10.1001/jama.2015.8009